Clinical trials and investment trends for novel CAR-T and TCR therapies

Eric NormanFoCUS, Research Briefs


Compared to small-molecule therapies, the nature of CAR-T/TCR therapies is such that they can be diversified with lower probability of failure in the clinic.

Many companies and academic entities are running clinical trials with different CAR- T/TCR products that often target the same disease.

A second wave of financial investments in CAR-T/TCR products has emerged alongside two early product approvals. Payers must be cognizant of future products emerging from the pipeline, expansion of indications, and the expected toll on their budgets.

Download FoCUS Research Brief 2018F212v030

Share the research